Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome
Open accessThe DOI matches its Crossref record; 24 of the 26 references it cites were found in a registry or an index.
Abstract
OBJECTIVE—We explored whether cardiovascular disease (CVD) risk and the effects of fenofibrate differed in subjects with and without metabolic syndrome and according to various features of metabolic syndrome defined by the Adult Treatment Panel III (ATP III) in subjects with type 2 diabetes in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. RESEARCH DESIGN AND METHODS—The prevalence of metabolic syndrome and its features was calculated. Cox proportional models adjusted for age, sex, CVD status, and baseline A1C levels were used to determine the independent contributions of metabolic syndrome features to total CVD event rates and the effects of fenofibrate. RESULTS—More than 80% of FIELD participants met the ATP III criteria for metabolic syndrome. Each ATP III feature of metabolic syndrome, apart from increased waist circumference, increased the absolute risk of CVD events over 5 years by at least 3%. Those with marked dyslipidemia (elevated triglycerides ≥2.3 mmol/l and low HDL cholesterol) were at the highest risk of CVD (17.8% over 5 years). Fenofibrate significantly reduced CVD events in those with low HDL cholesterol or hypertension. The largest effect of fenofibrate to reduce CVD risk was observed in subjects with marked dyslipidemia in whom a 27% relative risk reduction (95% CI 9–42, P = 0.005; number needed to treat = 23) was observed. Subjects with no prior CVD had greater risk reductions than the entire group. CONCLUSIONS—Metabolic syndrome components identify higher CVD risk in individuals with type 2 diabetes, so the absolute benefits of fenofibrate are likely to be greater when metabolic syndrome features are present. The highest risk and greatest benefits of fenofibrate are seen among those with marked hypertriglyceridemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Potential use of fibrates to reduce TG levels is quite limited, due to the risk of myopathy if given with statins and the little benefit demonstrated in RCTs, aside from sub-group analysis including subjects with very high TG levels.200,270,271”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [270]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Specifically, the five year FIELD Study, which evaluated 9,795 subjects with type 2 diabetes who were 50–75 years of age, demonstrated a reduction of 24% of non-fatal myocardial infraction (MI) for those receiving FF-compared to placebo (p=0.01).”
From Fenofibrate and metabolic syndrome (2010) · cites this paper as [46]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, a post hoc analysis of data from the FIELD study suggested a benefit for patients with both elevated triglyceride levels and low HDL cholesterol levels.12”
From Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus (2010) · cites this paper as [12]
The cited source says what the claim attributes to it.
In the citing paper
“Elevation of TGs or low HDL-C is seen in about half of subjects with T2DM. 351”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [351]
The cited source says what the claim attributes to it.
In the citing paper
“In a post hoc analysis of the FIELD study, fenofibrate reduced CVD events by 27% in those with elevated TGs [>2.3 mmol/L (~204 mg/dL)] and reduced HDL-C (NNT ¼ 23).351”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [351]
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Collaborators, C. T. T. (. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60104-x · Cited by 2,081
Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
Hokanson, J. E., & Austin, M. A. (1996) · Journal of Cardiovascular Risk · doi:10.1097/00043798-199604000-00014 · Cited by 1,706
Alexander, C. M., Landsman, P. B., Teutsch, S. M., & Haffner, S. M. (2003) · Diabetes · doi:10.2337/diabetes.52.5.1210 · Cited by 1,475 · cited 1×
“National Health and Nutrition Examination Survey III survey and also in individuals with newly diagnosed diabetes (11,12).”
BackgroundAtherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk
Austin, M. A., King, M. C., Vranizan, K. M., & Krauss, R. M. (1990) · Circulation · doi:10.1161/01.cir.82.2.495 · Cited by 1,411 · cited 1×
“ies (8,14), presumably reflecting a tendency for high nonfasting triglyceride levels and higher numbers of remnant particles and may be associated with more extreme abnormalities in other biological processes (such as oxidative stress, inflammation, and hypercoagulability), leading to more aggressive atherosclerosis (…”
BackgroundSarwar, N., Danesh, J., Eiriksdottir, G., Sigurdsson, G., Wareham, N., Bingham, S., Boekholdt, S. M., Khaw, K.-T., & Gudnason, V. (2007) · Circulation · doi:10.1161/circulationaha.106.637793 · Cited by 1,408 · cited 1×
“ies (8,14), presumably reflecting a tendency for high nonfasting triglyceride levels and higher numbers of remnant particles and may be associated with more extreme abnormalities in other biological processes (such as oxidative stress, inflammation, and hypercoagulability), leading to more aggressive atherosclerosis (…”
Background
Cited by
Items 201–300 of 549
Consenso de expertos sobre propuestas para la mejora del manejo de la dislipemia aterogénica
Núñez-Cortés, J. M., Pedro‐Botet, J., Brea-Hernando, Á., Rodríguez, Á. D., González‐Santos, P., Hernández‐Mijares, A., Mantilla, T., Pintó, X., & Simó, R. (2013) · Revista Española de Cardiología · doi:10.1016/j.recesp.2013.06.014 · Cited by 34
Ferreira, J. P., Verma, S., FITCHETT, D. H., Ofstad, A. P., Lauer, S., Zwiener, I., George, J. T., Wanner, C., Zinman, B., & Inzucchi, S. E. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01174-6 · Cited by 33
Rupp, H. (2009) · Advances in Therapy · doi:10.1007/s12325-009-0045-2 · Cited by 34
Deerochanawong, C., Kim, S. G., & Chang, Y.-C. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0168 · Cited by 31
Plana, N., Ibarretxe, D., Cabré, A., Ruiz, E., & Masana, L. (2014) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2014.04.002 · Cited by 32
Pharmacological management of diabetic dyslipidemia
Filippatos, T. D., Florentin, M., Georgoula, M., & Elisaf, M. (2016) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1263565 · Cited by 33
Fruchart, J., Hermans, M. P., Fruchart‐Najib, J., & Kodama, T. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00897-x · Cited by 30
Reducing residual vascular risk in patients with atherogenic dyslipidemia: where do we go from here?
Hermans, M. P., & Fruchart, J. (2010) · Clinical Lipidology · doi:10.2217/clp.10.65 · Cited by 34
Seok, H., & Soo, B. (2013) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2013.37.5.326 · Cited by 27
Lambadiari, V., Korakas, E., & Tsimihodimos, V. (2020) · Nutrients · doi:10.3390/nu12082204 · Cited by 32
Zhang, J., Liu, Y.-Y., Sun, H., Li, S., Xiong, H., Yang, Z., Xiang, G., & Jiang, X. (2015) · Medical Science Monitor · doi:10.12659/msm.896071 · Cited by 28
Fanni, G., Rosato, R., Gentile, L., Anselmino, M., Frea, S., Ponzo, V., Pellegrini, M., Broglio, F., Pivari, F., Ferrari, G. M. D., et al. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02357-1 · Cited by 27
Approach to the diagnosis and management of lipoprotein disorders
Al-Waili, K., Al‐Rasadi, K., Awan, Z. A., & Genest, J. J. (2009) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e328329135a · Cited by 27
Gulizia, M. M., Colivicchi, F., Ricciardi, G., Giampaoli, S., Maggioni, A. P., Averna, M. R., Graziani, M. S., Ceriotti, F., Mugelli, A., Rossi, F., et al. (2017) · European Heart Journal Supplements · doi:10.1093/eurheartj/sux029 · Cited by 27
Chen, X., Zhao, Y., Sun, J., Jiang, Y., & Tang, Y. (2024) · Nutrition & Metabolism · doi:10.1186/s12986-024-00864-2 · Cited by 31
Yang, Y., Kim, H., Kim, S., & Moon, M. K. (2023) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2023.12.1.12 · Cited by 30
Tonkin, A. M., Hunt, D., Voysey, M., Kesäniemi, A., Hamer, A. W., Waites, J. H., Mahar, L., Mann, S., Glasziou, P., Forder, P., et al. (2012) · American Heart Journal · doi:10.1016/j.ahj.2011.12.004 · Cited by 25
Self-citationHigh-density lipoprotein therapeutics and cardiovascular prevention
Fazio, S., & Linton, M. F. (2010) · Journal of clinical lipidology · doi:10.1016/j.jacl.2010.08.004 · Cited by 28
Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia
Filippatos, T. D., & Elisaf, M. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.593509 · Cited by 26
Feng, X., Gao, X., Jia, Y., Zhang, H., Pan, Q., Yao, Z. J., Yang, N., Liu, J., Xu, Y., Wang, G., et al. (2015) · PPAR Research · doi:10.1155/2015/924131 · Cited by 27
Feng, X., Gao, X., Jia, Y., Zhang, H., Xu, Y., & Wang, G. (2016) · Medical Science Monitor · doi:10.12659/msm.897307 · Cited by 28
Origin and therapy for hypertriglyceridaemia in type 2 diabetes
Pang, J., Chan, D. C., & Watts, G. F. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i2.165 · Cited by 26
Inhibition of ApoCIII: the next PCSK9?
Moens, S. J. B., van Capelleveen, J. C., & Stroes, E. S. G. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000130 · Cited by 25
Management of Dyslipidemias in the Presence of the Metabolic Syndrome or Type 2 Diabetes
Matikainen, N., & Taskinen, M. (2012) · Current Cardiology Reports · doi:10.1007/s11886-012-0309-3 · Cited by 27
Self-citationLi, P., LUO, S., Pan, C., & Cheng, X. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.4466 · Cited by 26
Manoria, P. C., Chopra, H. K., Parashar, S.-R., Dutta, A. L., Pinto, B., Mullasari, A., & Prajapati, S. (2013) · Indian Heart Journal · doi:10.1016/j.ihj.2013.10.015 · Cited by 32
Pitavastatin and HDL: Effects on plasma levels and function(s)
Pirillo, A., & Catapano, A. L. (2017) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2017.05.001 · Cited by 26
Alsayed, N., Almahmeed, W. A., Alnouri, F., Al-Waili, K., Sabbour, H. M., Sulaiman, K., Zubaid, M., Ray, K. K., & Al‐Rasadi, K. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.11.022 · Cited by 25
Samson, S. L., Vellanki, P., Blonde, L., Hirsch, I. B., Hoang, T. D., Isaacs, S. D., Izuora, K. E., Wang, C. C. L., Ooi, C. P., Padilla, B. I., et al. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.01.006 · Cited by 34
Treatment of dyslipidemia in the elderly
Hong, S., Li, Q. C., & Xu, J. (2011) · 老年心脏病学杂志:英文版 · doi:10.3724/sp.j.1263.2011.00055 · Cited by 24
Statins in cardiometabolic disease: what makes pitavastatin different?
Ginsberg, H. N. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-s1-s1 · Cited by 25
Management of Hypertriglyceridemia for Prevention of Atherosclerotic Cardiovascular Disease
Brinton, E. A. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2015.09.012 · Cited by 24
Yang, Y., Kim, H., Kim, S., Moon, M. K., & Korean Society of Lipid and Atherosclerosis (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0448 · Cited by 26
Harmer, J. A., KEECH, A. C., Veillard, A., Skilton, M. R., Marwick, T. H., Watts, G. F., Meredith, I. T., & Celermajer, D. S. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.07.038 · Cited by 22
Self-citationManagement of Hypertriglyceridemia for Prevention of Atherosclerotic Cardiovascular Disease
Brinton, E. A. (2015) · Cardiology Clinics · doi:10.1016/j.ccl.2015.02.007 · Cited by 23
Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East
Sayed, N., Waili, K. A., Alawadi, F., Al-Ghamdi, S. M. G., Almahmeed, W. A., Alnouri, F., Rukhaimi, M. A., Al‐Rasadi, K., Awan, Z. A., Farghaly, M., et al. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.09.081 · Cited by 23
Fenofibrate and Dyslipidemia: Still a Place in Therapy?
Tarantino, N. M., Santoro, F., Correale, M., Gennaro, L. D., Romano, S., Biase, M. D., & Brunetti, N. D. (2018) · Drugs · doi:10.1007/s40265-018-0965-8 · Cited by 21
Winkler, K. E., Schewe, T., Pütz, G., Ödünc, N., Schäfer, G., Siegel, E. G., Geisen, U., Abletshauser, C., & Hoffmann, M. M. (2009) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2009.02126.x · Cited by 21
Do Persons with Diabetes Benefit from Combination Statin and Fibrate Therapy?
Rosenblit, P. D. (2012) · Current Cardiology Reports · doi:10.1007/s11886-011-0237-7 · Cited by 22
Feitosa, M. F., An, P., Ordovás, J. M., Ketkar, S., Hopkins, P. N., Straka, R. J., Arnett, D. K., & Borecki, I. B. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.01.011 · Cited by 21
Leutner, M., Haug, N., Bellach, L., Dervić, E., Kautzky, A., Klimek, P., & Kautzky‐Willer, A. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11050328 · Cited by 24
Crakes, K. R., Pires, J., Quach, N., Ellis-Reis, R. E., Greathouse, R. L., Chittum, K. A., Steiner, J. M., Pesavento, P. A., Marks, S. L., Dandekar, S., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-92966-7 · Cited by 25
Ueno, H., Saitoh, Y., Mizuta, M., Shiiya, T., Noma, K., Mashiba, S., Kojima, S., & Nakazato, M. (2011) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2011.03.012 · Cited by 22
Optimal pharmacotherapy to combat the atherogenic lipid triad
Chapman, M. J., Redfern, J. S., McGovern, M. E., & Giral, P. (2011) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e32834965e9 · Cited by 18
Reyes‐Soffer, G., Rondon-Clavo, C., & Ginsberg, H. N. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.563506 · Cited by 19
Feingold, K. R. (2017) · Europe PMC (PubMed Central) · Cited by 18
Hussain, A., & Ballantyne, C. M. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-100119-013612 · Cited by 22
‘Trig-onometry’: non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia
Jacobson, T. A. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02547.x · Cited by 18
Triglycerides: How Much Credit Do They Deserve?
Kohli, P., & Cannon, C. P. (2012) · Medical Clinics of North America · doi:10.1016/j.mcna.2011.11.006 · Cited by 18
Environmental Factors Modifying HDL Functionality
Kostara, C. E., Kosmas, C. E., Sourlas, A., & Guzman, E. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666210714155422 · Cited by 18
Atherogenic Dyslipidemia and Combination Pharmacotherapy in Diabetes: Recent Clinical Trials
Hamilton, S. J., & Watts, G. F. (2013) · The Review of Diabetic Studies · doi:10.1900/rds.2013.10.191 · Cited by 17
Rydén, L., estable, G. D. T. D. L. S. E. D. C. S. D. Y. T. D. L. C. I., Grant, P. J., Anker, S. D., Berne, C., Cosentino, F., Danchin, N., Deaton, C., Escaned, J., Hammes, H. P., et al. (2014) · Revista Española de Cardiología · doi:10.1016/j.recesp.2013.10.015 · Cited by 37
Self-citationSaeed, A., Virani, S. S., Mulukutla, S. R., & Chow, C. K. (2021) · Current Diabetes Reviews · doi:10.2174/1573399817999210112192419 · Cited by 23
Management of the statin-intolerant patient
Smiley, W. H., Khan, B. V., & Sperling, L. S. (2009) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-009-0027-3 · Cited by 19
van Wijk, J. P. H., Hoepelman, A. I. M., de Koning, E. J. P., Dallinga‐Thie, G. M., Rabelink, T. J., & Cabezas, M. C. (2010) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.110.216192 · Cited by 17
Milonas, D., & Τζιόμαλος, Κ. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1582028 · Cited by 17
Chan, D. C., Watts, G. F., Ooi, E. M. M., Rye, K., Ji, J., Johnson, A. G., & Barrett, P. H. R. (2009) · Diabetes Care · doi:10.2337/dc09-0519 · Cited by 17
Lessons from PROMINENT and prospects for pemafibrate
Fruchart, J.-C., Fruchart-Najib, J., Yamashita, S., Libby, P., Yokote, K., Kodama, T., Tomita, Y., Ridker, P. M., Hermans, M. P., & Zambon, A. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02305-z · Cited by 16
Fiévet, C., & Staels, B. (2009) · Current Atherosclerosis Reports · doi:10.1007/s11883-009-0043-5 · Cited by 19
Rhainds, D., Arsenault, B. J., Brodeur, M. R., & Tardif, J. (2012) · Future Cardiology · doi:10.2217/fca.12.25 · Cited by 20
Ballantyne, C. M., Jones, P. H., Kelly, M. T., Setze, C. M., Lele, A., Thakker, K. M., & Stolzenbach, J. C. (2011) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-011-6280-1 · Cited by 16
Recent Advances in the Treatment of Atherogenic Dyslipidemia in Type 2 Diabetes Mellitus
Wanner, C., & Krane, V. (2011) · Kidney & Blood Pressure Research · doi:10.1159/000326849 · Cited by 19
Should raising high-density lipoprotein cholesterol be a matter of debate?
Athyros, V. G., Katsiki, N., Karagiannis, A. I., & Mikhailidis, D. P. (2012) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0b013e3283522422 · Cited by 17
Chang, C., Lin, X.-R., Lin, Y.-L., Fang, W.-H., Lin, S., Chang, S., & Kao, J. (2018) · PLoS ONE · doi:10.1371/journal.pone.0192740 · Cited by 17
Effects of Bauhinia forficata Link Tea on Lipid Profile in Diabetic Patients
Mariángel, P. C., Avello, M., Morales-León, F., Fernández, P., Zapata, L. V., & Pastene, E. (2019) · Journal of Medicinal Food · doi:10.1089/jmf.2018.0111 · Cited by 18
Statin Combination Therapy and Cardiovascular Risk Reduction
Toth, P. P., Farnier, M., Tomassini, J. E., Foody, J. M., & Tershakovec, A. M. (2016) · Future Cardiology · doi:10.2217/fca-2015-0011 · Cited by 17
How Can We Improve the Management of Vascular Risk in Type 2 Diabetes: Insights from FIELD
Steiner, G. A. (2009) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-009-6190-7 · Cited by 22
Combination Lipid Therapy in Type 2 Diabetes
Clearfield, M. B. (2010) · Current Atherosclerosis Reports · doi:10.1007/s11883-010-0139-y · Cited by 16
Joint Associations of APOC3 and LDL-C–Lowering Variants With the Risk of Coronary Heart Disease
Wang, W., Li, R. P., Song, Z., Huang, N., Huang, T., Hua, X., & Tang, Y.-D. (2025) · JAMA Cardiology · doi:10.1001/jamacardio.2025.0195 · Cited by 16
Dislipemia en población diabética tratada con estatinas. Resultados del estudio DYSIS en España
Millán, J., Alegría, E., Guijarro, C., Lozano, J. V., Vitale, G. C., González-Timón, B., & González‐Juanatey, J. R. (2012) · Medicina Clínica · doi:10.1016/j.medcli.2012.09.030 · Cited by 22
Davidson, M. H., Rosenson, R. S., Maki, K. C., Nicholls, S. J., Ballantyne, C. M., Setze, C. M., Carlson, D. M., & Stolzenbach, J. C. (2012) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-012-6395-z · Cited by 15
Chan, J. C. N., Chan, S. P., Deerochanawong, C., Go, R. T., Lee, K., Ronald, C. W., Pan, C., Sheu, W. H., & Barter, P. J. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.05.034 · Cited by 17
World Congress on Insulin Resistance, Diabetes, and Cardiovascular Disease
Bloomgarden, Z. T. (2011) · Diabetes Care · doi:10.2337/dc11-1306 · Cited by 15
Dong, T., Lyu, J., Imachi, H., Kobayashi, T., Fukunaga, K., Sato, S., Ibata, T., Yoshimoto, T., Yonezaki, K., Iwama, H., et al. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.09.015 · Cited by 16
Pharmacokinetics of current and emerging treatments for hypercholesterolemia
Tomlinson, B., Chan, P., Zhang, Y., Liu, Z., & Lam, C. W. K. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1749261 · Cited by 17
Beyond statin therapy: a review of the management of residual risk in diabetes mellitus
Judge, E. P., Phelan, D. M. J., & O'Shea, D. B. (2010) · Journal of the Royal Society of Medicine · doi:10.1258/jrsm.2010.100033 · Cited by 18
Strategies to overcome statin intolerance
Agouridis, A. P., Nair, D. R., & Mikhailidis, D. P. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.1027685 · Cited by 15
Bril, F., Berg, G. A., Barchuk, M., & Nogueira, J. P. (2025) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2025.14.1.5 · Cited by 17
Downing, N. S., Cheng, T. M., Krumholz, H. M., Shah, N. D., & Ross, J. S. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.1371 · Cited by 19
The Use of Fibric Acid Derivatives in Cardiovascular Prevention
Khoury, N., & Goldberg, A. C. (2011) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-011-0128-7 · Cited by 16
Davidson, M. H., Phillips, A., Kling, D. F., & Maki, K. C. (2014) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2014.942640 · Cited by 14
Fibrates in CVD: a step towards personalised medicine
Staels, B. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60758-1 · Cited by 17
Brautbar, A., Virani, S. S., Belmont, J. W., Nambi, V., Jones, P. H., & Ballantyne, C. M. (2012) · Journal of Lipid Research · doi:10.1194/jlr.m020404 · Cited by 14
Kastelein, J. J. P., Hallén, J., Vige, R., Fraser, D. A., Zhou, R., Hustvedt, S. O., Orloff, D. G., & Bays, H. E. (2016) · Cardiology · doi:10.1159/000445047 · Cited by 15
Pedoman Tatalaksana Dislipidemia PERKI 2013
Erwinanto, E., Santoso, A., Putranto, J. N., Tedjasukmana, P., Suryawan, R., Rifqi, S., & Kasiman, S. (2015) · Indonesian Journal of Cardiology · doi:10.30701/ijc.v34i4.385 · Cited by 18
Ma, S., Liu, S., Wang, Q., Chen, L., Yang, P., & Sun, H. (2019) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13042 · Cited by 15
Orsi, E., Penno, G., Solini, A., Bonora, E., Fondelli, C., Trevisan, R., Vedovato, M., Cavalot, F. L., Morano, S., Baroni, M. G., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01224-7 · Cited by 16
Henry, D., Baugé, E., Hennuyer, N., Ory, K., Derudas, B., Vallez, E., Deprince, A., Lefèbvre, P., Haas, J. T., Staels, B., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adj8192 · Cited by 14
Koh, S. M., Chung, S. H., Yum, Y., Park, S.-J., Joo, H. J., Kim, Y., & Kim, E. J. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01681-8 · Cited by 17
Krysiak, R. G., Szkróbka, W., & Okopień, B. (2018) · Pharmacological Reports · doi:10.1016/j.pharep.2018.09.004 · Cited by 14
Riesgo cardiovascular residual de origen lipídico. Componentes y aspectos fisiopatológicos
Hernández‐Mijares, A., Ascaso, J. F., Blasco, M., Brea, Á., Rodríguez, Á. D., Mantilla, T., Pedro‐Botet, J., Pintó, X., & Millán, J. (2018) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2018.06.007 · Cited by 17
Irvin, M. R., Zhang, Q., Kabagambe, E. K., Perry, R. T., Straka, R. J., Tiwari, H. K., Borecki, I. B., Shimmin, L. C., Stuart, C., Zhong, Y., et al. (2012) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e328351a486 · Cited by 13
Dhyani, N., Saidullah, B., Fahim, M., & Omanwar, S. (2019) · Human & Experimental Toxicology · doi:10.1177/0960327119860173 · Cited by 13
Vera, A. S. D., Alemán, J. A., Segura‐Fragoso, A., de Esteban, J. P. M., Couso, F. J. L., Rabanal, M. D. S. G., Vera, L. A. D., & Matta-Solis, H. H. (2020) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2019.04.006 · Cited by 13
Research Progress of Hypertriglyceridemia and Coronary Heart Disease
Ji, Y., & Bai, C. (2018) · Heart and Mind · doi:10.4103/hm.hm_2_19 · Cited by 14
Kim, N. H., Kim, J. Y., Choi, J., & Kim, S. G. (2023) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad090 · Cited by 17
HDL: To Treat or Not To Treat?
Pirillo, A., Tibolla, G., Norata, G. D., & Catapano, A. L. (2014) · Current Atherosclerosis Reports · doi:10.1007/s11883-014-0429-x · Cited by 12
Hyperlipidaemia and cardiovascular disease: do fibrates have a role?
Saha, S. A., & Arora, R. R. (2011) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32834701c3 · Cited by 18
Use of Expert Consensus to Improve Atherogenic Dyslipidemia Management
Núñez-Cortés, J. M., Pedro‐Botet, J., Brea-Hernando, Á., Rodríguez, Á. D., González‐Santos, P., Hernández‐Mijares, A., Mantilla, T., Pintó, X., & Simó, R. (2013) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2013.06.011 · Cited by 13
Exploring the Management of Statin Intolerant Patients: 2016 and Beyond
Katsiki, N., Athyros, V. G., & Karagiannis, A. I. (2016) · Current Vascular Pharmacology · doi:10.2174/1570161114666160226150028 · Cited by 12
Metadata
- Authors
- Scott, R., O'Brien, R., Fulcher, G., Pardy, C., d'Emden, M., Tse, D., Taskinen, M.-R., Ehnholm, C., Keech, A., & on behalf of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators
- Affiliations
- Christchurch Hospital (NZ)
- Department of Medicine, Austin Hospital, University of Melbourne, Melbourne, Australia
- The University of Sydney (AU)
- Endocrine Research Unit, Royal Brisbane Hospital, Brisbane, Australia
- Helsinki University Hospital (FI)
- Department of Molecular Medicine, National Public Health Institute, Biomedicum, Helsinki, Finland
- Corresponding author
- Scott, Russell
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2009-03-01
- Volume
- 32
- Issue
- 3
- Pages
- 493-498
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2646035
- OpenAlex
- W1975018096
- Cited by
- 551
- References
- 26
- Citations by year
- 2026: 10 · 2025: 13 · 2024: 15 · 2023: 20 · 2022: 12 · 2021: 23 · 2020: 32 · 2019: 34 · 2018: 28 · 2017: 31 · 2016: 32 · 2015: 43 · 2014: 41 · 2013: 41 · 2012: 38
- FWCI
- 33.39
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-nd)
- Funders
- Medical Research Council
- National Health and Medical Research Council
- National Medical Research Council
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- fenofibrate, type 2 diabetes, metabolic syndrome, cardiovascular risk, hypertriglyceridemia, dyslipidemia, low HDL cholesterol, hypertension, field trials, NCEP ATP III criteria
- MeSH terms
- Hypolipidemic Agents, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Humans, Male, Fenofibrate, Metabolic Syndrome, Dyslipidemias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.